Industry Shares Early Take on FDA’s Draft Decentralized Trial Guidance

The FDA’s long-awaited draft guidance on decentralized trials (DCT) is finally out and industry experts say that while the guidance has done many things right, recommendations on how sponsors monitor remote locations, such as in patients’ homes, may draw industry pushback.
Source: Drug Industry Daily